NYSE:NUVBPharmaceuticals
Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity?
In March 2026, Eisai and Nuvation Bio reported that the European Medicines Agency validated their Marketing Authorisation Application for taletrectinib to treat advanced ROS1-positive non-small cell lung cancer, following existing approvals in the US, China and Japan.
This regulatory milestone could broaden taletrectinib’s geographic reach under Eisai’s licensing deal, potentially deepening Nuvation Bio’s role in targeted lung cancer treatment across Europe and other Eisai territories.
We’ll...